Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Secretome from human placenta-derived mesenchymal stem cells repairs mechanically induced meniscus injury in mice by activating the proliferation and suppressing the apoptosis of endogenous meniscus progenitor cells

Chen WH., Lai WY., Le DC., Hsing JC., Ngo MT., Kao CX.

Prospective Study on Osteoarthritis, Meniscus Injury, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Stem Cell Res Ther (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41088346
PMCID
PMC12523042
DOI
10.1186/s13287-025-04688-6

Abstract (original English)

Background Meniscus diseases present certain therapeutic limitations. Although meniscectomy is the primary treatment option for meniscus injury (MI), this approach may accelerate the development of osteoarthritis and other degenerative joint diseases, and its therapeutic efficacy remains controversial. While human mesenchymal stem cells (MSCs) have emerged as a promising treatment option for MI, particularly in promoting cell proliferation and preventing apoptosis, their effect on activating endogenous meniscus progenitor cells (MPCs) to ameliorate MI and the underlying mechanisms remain unclear. Methods The secretome was collected from human placenta-derived MSCs (pcMSCs). A cellular model of MI was established by challenging mouse MPCs with H 2 O 2 . Male C57BL/6 mouse model of MI was established by mechanically destabilizing the medial meniscus (DMM). Protein expression was analyzed through Western blotting, flow cytometry, and immunohistochemistry staining. After secretome administration, behavioral activity was assessed through gait analysis and rotarod tests. Key secretome factors were identified through cytokine arrays and microRNA (miRNA) analysis. Results The pcMSC secretome significantly mitigated MI in both cellular and mouse models, as indicated by gait analysis (P Conclusions To the best of our knowledge, this is the first study demonstrating that the human pcMSC s

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Mesenchymal Stem CellsPlacentaAnimalsMice, Inbred C57BLHumansMiceDisease Models, AnimalMesenchymal Stem Cell TransplantationApoptosisCell Proliferation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research